<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The effects of the insulin resistance index on the virologic response to entecavir in patients with hBeag-positive chronic hepatitis B and nonalcoholic fatty liver disease</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-30">30 August 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li-Yao</forename><surname>Zhu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of hepatology</orgName>
								<orgName type="institution">The Fourth People&apos;s hospital of huai&apos;an</orgName>
								<address>
									<addrLine>huai&apos;an</addrLine>
									<settlement>Jiangsu</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Gang</forename><surname>Wang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of gastroenterology</orgName>
								<orgName type="institution" key="instit1">shanghai Tongren hospital</orgName>
								<orgName type="institution" key="instit2">shanghai Jiao Tong University school of Medicine</orgName>
								<address>
									<settlement>shanghai</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li-Qing</forename><surname>Wei</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Medical laboratory</orgName>
								<orgName type="institution" key="instit1">The central hospital of Wuhan</orgName>
								<orgName type="institution" key="instit2">Tongji Medical college</orgName>
								<orgName type="institution" key="instit3">huazhong University of science and Technology</orgName>
								<address>
									<addrLine>Wuhan, hubei</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><surname>Zhou</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of hepatology</orgName>
								<orgName type="institution">The Fourth People&apos;s hospital of huai&apos;an</orgName>
								<address>
									<addrLine>huai&apos;an</addrLine>
									<settlement>Jiangsu</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Jie</forename><surname>Dai</surname></persName>
							<email>daiweijie_yy@163.com</email>
							<affiliation key="aff3">
								<orgName type="department">Department of gastroenterology</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yu</forename><surname>Zhang</surname></persName>
							<email>zhangxiaoyu_ey@163.com</email>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of gastrointestinal surgery</orgName>
								<orgName type="department" key="dep2">Department of General Surgery</orgName>
								<orgName type="department" key="dep3">The Affiliated huai&apos;an hospital of Xuzhou Medical college</orgName>
								<address>
									<addrLine>62 south huaihai road, huai&apos;an</addrLine>
									<postCode>223002</postCode>
									<settlement>Jiangsu</settlement>
									<country>People&apos;s republic of china</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of gastroenterology, huai&apos;an First People&apos;s hospital, nanjing Medical University</orgName>
								<address>
									<addrLine>6 West Beijing road, huaiyin District, huai&apos;an 223300</addrLine>
									<settlement>Jiangsu</settlement>
									<country>People&apos;s republic of china</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The effects of the insulin resistance index on the virologic response to entecavir in patients with hBeag-positive chronic hepatitis B and nonalcoholic fatty liver disease</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-30">30 August 2016</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.2147/DDDT.S114761</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>hepatitis B virus</term>
					<term>chronic</term>
					<term>fatty liver</term>
					<term>entecavir</term>
					<term>insulin resistance index</term>
				</keywords>
			</textClass>
			<abstract>
				<p>To further observe and verify the effect of nonalcoholic fatty liver disease (NAFLD) on the response to antiviral therapy in patients with chronic hepatitis B (CHB) and investigate the relationship between the virologic response and insulin resistance. Patients and methods: A retrospective study was adopted and 61 NAFLD patients with HBeAg-positive CHB were included as the observation group (group A), and 64 patients with simple CHB were included as the control group (group B). Results: After 12 weeks of treatment with entecavir, the total virologic response rate in group A was statistically significantly lower than that in group B (P0.05). During weeks 24-96, the difference was not statistically significant (P0.05). In weeks 48 and 96, there was no significant difference in the HBeAg seroconversion rates between the two groups (P0.05). In weeks 12 and 24, there was also no significant difference in the alanine transaminase (ALT) normalization rate between the two groups (P0.05). Then, in weeks 48 and 96, the ALT normalization rate of group A was obviously lower than that of group B (P0.05). Group A patients were divided into group A1 (M) and group A2 (M) according to the median value (M=2.79) of the baseline homeostatic model assessment method insulin resistance levels. In weeks 48 and 96, the ALT normalization rate of group A1 was significantly higher than that of group A2 (P0.05). The correlation coefficient (r) of the baseline homeostatic model assessment method insulin resistance level and the severity of fatty liver in group A was 0.426 (P=0.001). Conclusion: NAFLD cannot affect the long-term total virologic response rate and HBeAg seroconversion rate in CHB patients treated with entecavir but can reduce the long-term biochemical response rate, which has a positive correlation with the severity of fatty liver and the insulin resistance index.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>After years of effective prevention and control, the incidence of patients with HBsAg has been significantly reduced; however, chronic hepatitis B (CHB) is still the primary chronic liver disease that threatens people's health in the People's Republic of China. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> With the improvement in living standards, the morbidity of fatty liver disease has gradually increased, and it has become the second most common chronic liver disease surpassed only by hepatitis, especially for nonalcoholic fatty liver disease (NAFLD) due to an improper diet and lifestyle. <ref type="bibr" target="#b2">3</ref> Definitions of NAFLD have been proposed using biochemical criteria and hepatic imaging, such as ultrasonography (US), computed tomography, and magnetic resonance imaging. <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> Among these definitions, the US definition has been used most frequently in Chinese research studies, <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b12">12</ref> and this approach has been endorsed by the Asia-Pacific regional guidelines. <ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> NAFLD is commonly associated with type II diabetes mellitus and conditions associated with metabolic syndrome. CHB is frequently associated with hepatic steatosis. <ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref> Long-term studies of obese patients with the spectrum of NAFLD have shown that the progression of liver disease is predominantly observed in patients with biopsy-proven nonalcoholic steatohepatitis. As a result, the number of patients suffering from CHB with NAFLD has increased, and the complexity of liver disease has expanded, which introduces new challenges to the clinical diagnosis and treatment. NAFLD appears to be associated with insulin resistance and represents the hepatic manifestation of metabolic syndrome. Hepatic steatosis is significantly associated with entecavir treatment failure, and the metabolic factors seem to be independent of hepatic steatosis in CHB patients, therefore requiring a specific antiviral strategy for CHB patients with NAFLD. <ref type="bibr" target="#b16">16</ref> Not surprisingly, patients with NAFLD are at a high risk of developing metabolic complications, which may be much higher than the risk of developing liver cirrhosis. <ref type="bibr" target="#b2">3</ref> However, a recent study <ref type="bibr" target="#b17">17</ref> in Turkey found that virologic replication decreases in CHB patients in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir along with tenofovir treatment. Therefore, in the present study, we analyzed the effect of NAFLD on the response to antiviral therapy of CHB through a retrospective clinical analysis and explored the relationship between the differences in response to therapy and insulin resistance index.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient selection</head><p>Between June 2008 and June 2013, 125 HBeAg-positive patients with CHB received entecavir as an initial treatment at The Fourth People's Hospital of Huai'an, Jiangsu province. Of them, 61 patients (48.8%) emerged with NAFLD. This retrospective study was performed with the approval of the ethics committee of The Fourth People's Hospital of Huai'an. The ethics committee of The Fourth People's Hospital of Huai'an did not require patient consent be obtained for this study, as this was a retrospective study, and all data was anonymous.</p><p>The inclusion criteria were as follows: 1) age between 18 years and 60 years; 2) a standard diagnosis of CHB and antiviral treatment indications according to the CHB prevention guidelines (2015), <ref type="bibr" target="#b18">18</ref> including i) patients with a history of CHB or those who are HBsAg positive for 6 months, without normal antiviral therapy; ii) patients who are HBeAg positive; iii) alanine transaminase (ALT) two or more times of the upper limit of normal; iv) hepatitis B virus (HBV) DNA 10 5 copies/mL; and v) the exclusion of other factors that lead to increases in ALT, such as another infection with hepatotropic viruses, alcohol, liver toxic drugs, autoimmune liver disease, and hepatolenticular degeneration; and 3) for patients with both CHB and fatty liver disease, the diagnosis of fatty liver must be in accordance with the diagnosis of nonalcoholic fatty liver disease (revised in 2010), 9,10 which must meet two or more of the three abdominal ultrasound findings in the diagnostic criteria, including i) the echo of the near-field liver is enhanced and stronger than the kidney; ii) the echo of the far-field liver is gradually attenuated; and (iii) the intrahepatic duct structure display is not clear.</p><p>A diagnosis of fatty liver by US is defined by the presence of at least two of the following three abnormal findings: diffusely increased echogenicity "bright" liver with liver echogenicity greater than the kidney or spleen, vascular blurring, and deep attenuation of the ultrasound signal. <ref type="bibr" target="#b5">5</ref> In addition, the dividing standards of fatty liver based on US <ref type="bibr" target="#b22">19</ref> are as follows: in the mild fatty liver, the liver and hepatorenal echogenicity is increased and the diaphragm is shown clearly; in the moderate fatty liver, the echo shows an enhancement in the anterior region of the liver and the hepatorenal contrast but a weakening in the posterior region, and the diaphragm is shown less clearly; in the serious fatty liver, the echo is increased in the anterior region of the liver and weakened in the posterior region, and the diaphragm and structure of the intrahepatic bile duct are not shown clearly. All patients provided verbal informed consent to the antiviral treatment.</p><p>In this retrospective study, we assigned 61 patients with CHB and NAFLD into group A and 64 patients with only CHB into group B. We observed the effects of NAFLD in CHB patients treated with entecavir on the virology, serology, and biochemical responses. Hepatitis B virus serum markers (HBsAG, anti-HBs, HBeAg, anti-HBe, and anti-HBc) were tested by enzyme-linked immunosorbent assay. The fluorescent quantitative polymerase chain reaction test was used to test the serum HBV-DNA level. ALT, fasting blood glucose (FBG), concentrations of triglyceride, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in serum were measured using an automatic serum biochemical assay device. Using the radioimmunity method to determine the fasting insulin level, we then estimated insulin sensitivity by homeostasis model assessment method insulin resistance (HOMA-IR = fasting serum insulin × FBG/22.5). Standard methods were used to measure the height, waist circumference, and body mass. Body mass index = body mass (kg)/height (m). <ref type="bibr" target="#b1">2</ref> All patients' liver ultrasound results were evaluated by an ultrasound doctor, and unified diagnostic reports were issued. The evaluation criteria were as follows: biochemical response to the serum ALT returned to normal; complete virologic response referred to the serum DNA-HBV load of 500 copies/mL; and HBeAg seroconversion referred to HBeAg negative and anti-HBe positive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>statistical analysis</head><p>The SPSS 21.0 statistical software (IBM Corporation, Armonk, NY, USA) was used for the statistical analysis. The measurement data were shown as mean ± standard deviation, the mean value of the two samples was compared by t-test, and the rate was compared by χ 2 test. Spearman correlation analysis was used to compare the correlation between the severity of fatty liver and the HOMA-IR index. All statistical tests were two sided and evaluated at the 0.05 alpha level.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The two groups were well-matched in terms of age, sex, ALT levels, HBV-DNA levels, genotyping, and low-density lipoprotein cholesterol levels (P0.05). The patients in group A showed a higher level of body mass index, waist circumference, fasting serum insulin, FBG, HOMA-IR, triglyceride, total cholesterol, and high-density lipoprotein cholesterol compared with group B (P0.05), and all these variables were statistically significantly different. The propensity scores generated from the variables before antiviral therapy are listed in <ref type="table" target="#tab_0">Table 1</ref>.</p><p>In both group A and group B, the HBV-DNA untestable rate (HBV-DNA level 500 copies/mL) increased gradually after treatment with entecavir. However, there was a difference in the HBV-DNA untestable rate at different follow-up time points. After 12 weeks of entecavir therapy, the total virologic response rate in group A was lower than that in group B (group A 32.8% vs group B 51.6%, P=0.034). However, after 24, 48, and 96 weeks, the differences were not statistically significant (group A 52.5%, 62.3%, 82.0% vs group B 64.1%, 75.0%, 85.9%; P=0.188, P=0.125, P=0.545, respectively; <ref type="table" target="#tab_1">Table 2</ref>).</p><p>For both group A and group B, the HBeAg seroconversion rate increased gradually after entecavir treatment. The HBeAg seroconversion rate was equivalent for both groups at 48 and 96 weeks (group A 21.3%, 29.5% vs group B 23.4%, 32.8%; P=0.776, P=0.690, respectively; <ref type="table" target="#tab_2">Table 3</ref>).</p><p>After entecavir treatment, the ALT normalization rate increased gradually <ref type="table" target="#tab_3">(Table 4</ref>). An equivalent percentage of patients' serum ALT levels returned to normal in each cohort at 12 and 24 weeks (group A 50.8%, 55.7% vs group B 59.4%, 65.5%; P=0.336, P=0.258, respectively). However, at 48 and 96 weeks, the ALT normalization rates were significantly lower in group A than in group B (group A 65.6%, 82.0% vs group B 81.3%, 93.8%; P=0.047, P=0.043, respectively). PEGylated interferon treatment. Jin et al <ref type="bibr" target="#b16">16</ref> investigated the effect of hepatic steatosis, a common hepatocyte change in NAFLD, on antiviral therapy in patients with CHB. They found that hepatic steatosis is significantly associated with entecavir treatment failure and that metabolic factors are independent of hepatic steatosis in CHB patients, which calls for a specified antiviral strategy in CHB patients with NAFLD. The purpose of this study was to observe and verify the effects of NAFLD on the antiviral therapy response in patients with CHB and investigate the relationship between the response differences and the insulin resistance index. In our study, the HBV-DNA clearance rate was lower in patients with NAFLD than that of the CHB group at 12 weeks, but it was equivalent at 24, 48, and 96 weeks. The results indicated that NAFLD may affect the rate of early viral response in CHB, but it would not affect the long-term treatment virologic response rate. However, this result was not consistent with that of Jin et al. <ref type="bibr" target="#b16">16</ref> Considering the HBeAg seroconversion rate, we found that there were no significant differences between the two groups at 48 and 96 weeks, which suggested that NAFLD was not affecting patients' HBeAg seroconversion rate with CHB. Unfortunately, the aforementioned finding was also different from that of Jin et al. <ref type="bibr" target="#b16">16</ref>     According to the baseline level of the HOMA-IR median (M=2.79), the 61 patients in group A were divided into two groups (group A1, IR M, 31 patients and group A2, IR M, 30 patients). <ref type="table" target="#tab_4">Table 5</ref> shows that the A1 patients' ALT normalization rates were higher than those of A2 patients at 48 and 96 weeks (group A1 77.4%, 93.5% vs group A2 53.3%, 70.0%; P=0.048, P=0.017, respectively).</p><p>The 61 patients in group A were divided into three groups according to the severity of the fatty liver determined by ultrasonic results. Of them, 30 patients were categorized as mild, 22 patients were categorized as moderate, and 9 patients were categorized as severe. The severity of the pathological changes due to the fatty liver was positively correlated with HOMA-IR (r=0.426, P=0.001; <ref type="table" target="#tab_5">Table 6</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>The key to treating CHB is antiviral therapy, and there are many guidelines for treatment programs. However, there is no clear antiviral treatment program for CHB patients who also have NAFLD, and it is unknown whether the antiviral effect is affected by the fatty infiltration of the liver. Therefore, there is no consensus, and it has gradually become a hot issue of public concern.</p><p>Ates et al <ref type="bibr" target="#b23">20</ref> found that the occurrence of hepatic steatosis is significantly higher in CHB patients, and this association leads to a trend of decreased, but statistically insignificant, sustained virologic response rates to 48-week The ALT normalization rate indicated that there were significant differences between the two groups after treatment with entecavir for 48 and 96 weeks but showed an equivalent percentage at 12 and 24 weeks. The results we observed suggested that NAFLD did not affect the early biochemical response rate in CHB patients, which might be due to the early use of drugs to protect the liver and reduce enzymes. However, it might affect the long-term biochemical response rate, which is consistent with the results of related studies. <ref type="bibr" target="#b16">16</ref> According to the demographic information and baseline of the two groups, it was demonstrated that the occurrence of NAFLD was not related to viral factors and ALT levels, while the disorder of the metabolism and insulin resistance might play an important role. Further studies found that the level of insulin resistance was positively correlated with the severity of the fatty liver in group A (r=0.426, P=0.001). The subgroup analysis of group A indicated that the baseline levels of HOMA-IR and the biochemical responses were negatively correlated, which was more apparent when treatment period was longer.</p><p>Admittedly, there are many limitations to this study. First, the diagnosis may be biased without a liver biopsy at the baseline diagnosis. Furthermore, the sample of observed patients is small. Finally, there are differences in the conclusion when compared with related research. Future research should increase the number of observed patients and conduct liver biopsies at baseline to provide a reference for clinical diagnosis and treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>The results of this study indicated that NAFLD may decrease the total virologic response rate in patients with CHB over a short period of time, but it does not affect the long-term total virologic response rate and HBeAg seroconversion rate. NAFLD may not have a significant effect in the shortterm on the biochemical response rate in CHB patients, but it can decrease the biochemical response rate in long-term treatment, and the decrease in the biochemical response rate is related to the severity of NAFLD, especially the insulin resistance index. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>comparison of the data of the chB patients with and without nonalcoholic fatty liver disease</figDesc><table><row><cell></cell><cell>Group A (n=61)</cell><cell>Group B (n=64)</cell><cell>t</cell><cell>P-value</cell></row><row><cell>age (years), mean ± sD</cell><cell>39.26±10.39</cell><cell>39.61±10.87</cell><cell>0.18</cell><cell>0.05</cell></row><row><cell>sex</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male (n)</cell><cell>42</cell><cell>41</cell><cell>0.32</cell><cell>0.05</cell></row><row><cell>Female (n)</cell><cell>19</cell><cell>23</cell><cell></cell><cell></cell></row><row><cell>BMi (kg/m 2 ), mean ± sD</cell><cell>26.29±3.99</cell><cell>22.50±2.85</cell><cell>6.11</cell><cell>0.05</cell></row><row><cell>Wc (cm), mean ± sD</cell><cell>89.88±11.25</cell><cell>79.84±9.99</cell><cell>5.28</cell><cell>0.05</cell></row><row><cell>alT (U/l), mean ± sD</cell><cell>179.87±78.50</cell><cell>187.95±79.88</cell><cell>0.57</cell><cell>0.05</cell></row><row><cell>hBV-Dna (lg copies/ml), mean ± sD</cell><cell>6.24±0.78</cell><cell>6.20±0.64</cell><cell>0.31</cell><cell>0.05</cell></row><row><cell>genotyping</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>hBV genotype B (%)</cell><cell>38</cell><cell>42</cell><cell>0.15</cell><cell>0.05</cell></row><row><cell>hBV genotype c (%)</cell><cell>23</cell><cell>22</cell><cell></cell><cell></cell></row><row><cell>hOMa-ir, mean ± sD</cell><cell>3.67±3.89</cell><cell>2.07±1.98</cell><cell>3.6</cell><cell>0.05</cell></row><row><cell>Fins (mU/l), mean ± sD</cell><cell>15.46±10.93</cell><cell>9.03±7.36</cell><cell>3.84</cell><cell>0.05</cell></row><row><cell>FBg (mmol/l), mean ± sD</cell><cell>5.11±0.85</cell><cell>4.89±0.80</cell><cell>1.52</cell><cell>0.05</cell></row><row><cell>Tg (mmol/l), mean ± sD</cell><cell>1.80±0.95</cell><cell>1.33±0.64</cell><cell>3.29</cell><cell>0.05</cell></row><row><cell>Tc (mmol/l), mean ± sD</cell><cell>3.78±1.07</cell><cell>3.72±0.97</cell><cell>0.31</cell><cell>0.05</cell></row><row><cell>hDl-c (mmol/l), mean ± sD</cell><cell>0.86±0.34</cell><cell>1.07±0.35</cell><cell>3.32</cell><cell>0.05</cell></row><row><cell>lDl-c (mmol/l), mean ± sD</cell><cell>2.31±0.72</cell><cell>2.16±0.68</cell><cell>1.15</cell><cell>0.05</cell></row></table><note>Notes: group a: naFlD patients with hBeag-positive chB; group B: patients with simple chB. Abbreviations: chB, chronic hepatitis B; BMi, body mass index; Wc, waist circumference; alT, alanine transaminase; hBV, hepatitis B virus; hOMa-ir, homeostatic model assessment method insulin resistance; Fins, fasting serum insulin; FBg, fasting blood glucose; Tg, triglyceride; Tc, total cholesterol; hDl-c, high-density lipoprotein cholesterol; lDl-c, low-density lipoprotein cholesterol; naFlD, nonalcoholic fatty liver disease.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>comparison of the hBV-Dna untestable rate between the study groups at different follow-up time points</figDesc><table><row><cell></cell><cell>Group A</cell><cell>Group B</cell><cell>χ 2</cell><cell>P-value</cell></row><row><cell></cell><cell>(n=61)</cell><cell>(n=64)</cell><cell></cell><cell></cell></row><row><cell>12 weeks</cell><cell>20 (32.8%)</cell><cell>33 (51.6%)</cell><cell>4.508</cell><cell>0.034</cell></row><row><cell>24 weeks</cell><cell>32 (52.5%)</cell><cell>41 (64.1%)</cell><cell>1.731</cell><cell>0.188</cell></row><row><cell>48 weeks</cell><cell>38 (62.3%)</cell><cell>48 (75.0%)</cell><cell>2.349</cell><cell>0.125</cell></row><row><cell>96 weeks</cell><cell>50 (82.0%)</cell><cell>55 (85.9%)</cell><cell>0.366</cell><cell>0.545</cell></row><row><cell cols="5">Notes: group a: naFlD patients with hBeag-positive chB; group B: patients</cell></row><row><cell>with simple chB.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Abbreviations: chB, chronic hepatitis B; hBV, hepatitis B virus; naFlD,</cell></row><row><cell cols="2">nonalcoholic fatty liver disease.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>comparison of the hBeag seroconversion rate between the study groups at follow-up time points</figDesc><table><row><cell></cell><cell>Group A</cell><cell>Group B</cell><cell>χ 2</cell><cell>P-value</cell></row><row><cell></cell><cell>(n=61)</cell><cell>(n=64)</cell><cell></cell><cell></cell></row><row><cell>48 weeks</cell><cell>13 (21.3%)</cell><cell>15 (29.5%)</cell><cell>0.081</cell><cell>0.776</cell></row><row><cell>96 weeks</cell><cell>18 (23.4%)</cell><cell>21 (32.8%)</cell><cell>0.159</cell><cell>0.69</cell></row></table><note>Notes: group a: naFlD patients with hBeag-positive chB; group B: patients with simple chB. Abbreviations: chB, chronic hepatitis B; naFlD, nonalcoholic fatty liver disease.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc>comparison of the alT normalization rate between the study groups at different follow-up time points</figDesc><table><row><cell></cell><cell>Group A</cell><cell>Group B</cell><cell>χ 2</cell><cell>P-value</cell></row><row><cell></cell><cell>(n=61)</cell><cell>(n=64)</cell><cell></cell><cell></cell></row><row><cell>12 weeks</cell><cell>31 (50.8%)</cell><cell>38 (59.4%)</cell><cell>0.924</cell><cell>0.336</cell></row><row><cell>24 weeks</cell><cell>34 (55.7%)</cell><cell>42 (65.6%)</cell><cell>1.281</cell><cell>0.258</cell></row><row><cell>48 weeks</cell><cell>40 (65.6%)</cell><cell>52 (81.3%)</cell><cell>2.95</cell><cell>0.047</cell></row><row><cell>96 weeks</cell><cell>50 (82.0%)</cell><cell>60 (93.8%)</cell><cell>4.106</cell><cell>0.043</cell></row><row><cell cols="5">Notes: group a: naFlD patients with hBeag-positive chB; group B: patients</cell></row><row><cell>with simple chB.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Abbreviations: alT, alanine transaminase; chB, chronic hepatitis B; naFlD,</cell></row><row><cell cols="2">nonalcoholic fatty liver disease.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc>comparison of the alT normalization rate between group a patients with different baseline levels of hOMa-ir at follow-up time points</figDesc><table><row><cell>Group</cell><cell>Patients</cell><cell cols="2">ALT normalization</cell><cell>χ 2</cell><cell>P-value</cell></row><row><cell></cell><cell>(n)</cell><cell>rate, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>48 weeks</cell><cell>96 weeks</cell><cell></cell><cell></cell></row><row><cell>a1</cell><cell>31</cell><cell>24 (77.4%)</cell><cell>29 (93.5%)</cell><cell>3.918</cell><cell>0.048</cell></row><row><cell>a2</cell><cell>30</cell><cell>16 (53.3%)</cell><cell>21 (70.0%)</cell><cell>5.72</cell><cell>0.017</cell></row></table><note>Notes: group a: naFlD patients with hBeag-positive chB; group a1: hOMa-ir  median (2.79); group a2: hOMa-ir  median (2.79). Abbreviations: alT, alanine transaminase; chB, chronic hepatitis B; hOMa-ir, homeostatic model assessment method insulin resistance; naFlD, nonalcoholic fatty liver disease.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 6</head><label>6</label><figDesc>correlation analysis between the severity of fatty liver and hOMa-ir Note: spearman correlation analysis, r=0.426, P=0.001 (positive correlation). Abbreviation: hOMa-ir, homeostatic model assessment method insulin resistance.</figDesc><table><row><cell>Severity</cell><cell>Patients (n)</cell><cell>HOMA-IR,</cell></row><row><cell></cell><cell></cell><cell>mean ± SD</cell></row><row><cell>Mild</cell><cell>30</cell><cell>2.57±1.39</cell></row><row><cell>Moderate</cell><cell>22</cell><cell>3.54±2.11</cell></row><row><cell>serious</cell><cell>9</cell><cell>7.67±4.61</cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com Dovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head><p>This study was supported by the Key Project of Research and Development of Huai'an (HAS2015009).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p>The authors report no conflicts of interest in this work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug Design, Development and Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publish your work in this journal</head><p>Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaofeng</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shengli</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weizhong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Longde</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gang</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fuqiang</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianhua</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaohong</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuansheng</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fuzhen</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jing</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhiyuan</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingchen</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huaqing</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huiming</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuigao</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">C</forename><surname>Hadler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2013.08.012</idno>
		<idno type="PMID">23948229</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="J21" to="J28" />
			<date type="published" when="2013-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaofeng</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shengli</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weizhong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Longde</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gang</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fuqiang</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianhua</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaohong</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuansheng</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fuzhen</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jing</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhiyuan</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingchen</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huaqing</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huiming</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuigao</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">C</forename><surname>Hadler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2009.08.048</idno>
		<idno type="PMID">19729084</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">47</biblScope>
			<biblScope unit="page" from="6550" to="6557" />
			<date type="published" when="2009-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epidemiology of non-alcoholic fatty liver disease in China</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Gao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geoffrey</forename><forename type="middle">C</forename><surname>Farrell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2008.10.010</idno>
		<idno type="PMID">19014878</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Hepatology</title>
		<title level="j" type="abbrev">Journal of Hepatology</title>
		<idno type="ISSN">0168-8278</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="204" to="210" />
			<date type="published" when="2009-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association</title>
		<imprint/>
	</monogr>
	<note>Diagnostic criteria of nonalcoholic fatty liver disease</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Gan Zang Bing Za Zhi</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney Contrast</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshiaki</forename><surname>Yajima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kei</forename><surname>Ohta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takashi</forename><surname>Narui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryuzo</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masao</forename><surname>Ohtsuki</surname></persName>
		</author>
		<idno type="DOI">10.1620/tjem.139.43</idno>
		<idno type="PMID">6220488</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/tjem1920/139/1/139_1_43/_pdf" />
	</analytic>
	<monogr>
		<title level="j">The Tohoku Journal of Experimental Medicine</title>
		<title level="j" type="abbrev">Tohoku J. Exp. Med.</title>
		<idno type="ISSN">0040-8727</idno>
		<idno type="ISSNe">1349-3329</idno>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="43" to="50" />
			<date type="published" when="1983" />
			<publisher>Tohoku University Medical Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><forename type="middle">De</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><forename type="middle">Gao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lun</forename><forename type="middle">Gen</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">You</forename><forename type="middle">Ming</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheng</forename><forename type="middle">Wei</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bing</forename><forename type="middle">Yuan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><forename type="middle">Min</forename><surname>Mao</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1751-2980.2008.00331.x</idno>
		<idno type="PMID">18419645</idno>
		<idno type="ark">ark:/67375/WNG-79NHHG22-2</idno>
		<idno type="istexId">EFAAD949D27B9BA480E21EAD5374B7B40E7988BF</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Digestive Diseases</title>
		<title level="j" type="abbrev">J Dig Dis</title>
		<idno type="ISSN">1751-2972</idno>
		<idno type="ISSNe">1751-2980</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="108" to="112" />
			<date type="published" when="2008-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia?Pacific region: Executive summary</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geoffrey</forename><forename type="middle">C</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shivakumar</forename><surname>Chitturi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">Kk</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><forename type="middle">D</forename><surname>Sollano</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1746.2007.05002.x</idno>
		<idno type="PMID">17565629</idno>
		<idno type="ark">ark:/67375/WNG-45P1G784-Z</idno>
		<idno type="istexId">B22D498D7B5777F44CD0E7C1201151C9DD4BF280</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">J Gastroenterol Hepatol</title>
		<idno type="ISSN">0815-9319</idno>
		<idno type="ISSNe">1440-1746</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="775" to="777" />
			<date type="published" when="2007-06" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Non-alcoholic fatty liver disease in the Asia?Pacific region: Definitions and overview of proposed guidelines</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shivakumar</forename><surname>Chitturi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geoffrey</forename><forename type="middle">C</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Etsuko</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiji</forename><surname>Saibara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">Kk</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><forename type="middle">D</forename><surname>Sollano</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1746.2007.05001.x</idno>
		<idno type="PMID">17565630</idno>
		<idno type="ark">ark:/67375/WNG-7JX224P0-8</idno>
		<idno type="istexId">ADC3B47EFB9FD9E2F5BF8BE495B10EB67D1AC535</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">J Gastroenterol Hepatol</title>
		<idno type="ISSN">0815-9319</idno>
		<idno type="ISSNe">1440-1746</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="778" to="787" />
			<date type="published" when="2007-06" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><forename type="middle">Gao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ji</forename><forename type="middle">Dong</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">You</forename><forename type="middle">Ming</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bing</forename><forename type="middle">Yuan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lun</forename><forename type="middle">Gen</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><forename type="middle">Pin</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lik</forename><forename type="middle">Yuen</forename><surname>Chan</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1751-2980.2010.00476.x</idno>
		<idno type="PMID">21276207</idno>
		<idno type="ark">ark:/67375/WNG-MVMSCNMH-2</idno>
		<idno type="istexId">C7304D5E49B51EF3A5C063FB625D99E3D36CDB15</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Digestive Diseases</title>
		<idno type="ISSN">1751-2972</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="38" to="44" />
			<date type="published" when="2011-01-30" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note>J Dig Dis</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Jian-Gao F</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Gan Zang Bing Za Zhi</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="163" to="166" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">How common is non-alcoholic fatty liver disease in the Asia?Pacific region and are there local differences?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deepak</forename><forename type="middle">N</forename><surname>Amarapurkar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Estsuko</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laurentius</forename><forename type="middle">A</forename><surname>Lesmana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><forename type="middle">D</forename><surname>Sollano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pei-Jer</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Khean-Lee</forename><surname>Goh</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1746.2007.05042.x</idno>
		<idno type="PMID">17565631</idno>
		<idno type="ark">ark:/67375/WNG-6S4RDB1W-R</idno>
		<idno type="istexId">3F0CE7A28DCF946C1BFA0CADE367D3D561410C85</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">J Gastroenterol Hepatol</title>
		<idno type="ISSN">0815-9319</idno>
		<idno type="ISSNe">1440-1746</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="788" to="793" />
			<date type="published" when="2007-06" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">What are the risk factors and settings for non-alcoholic fatty liver disease in Asia?Pacific?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Gao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiji</forename><surname>Saibara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shivakumar</forename><surname>Chitturi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Byong</forename><forename type="middle">Ik</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">J Y</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chutaputti</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1746.2007.04952.x</idno>
		<idno type="PMID">17498218</idno>
		<idno type="ark">ark:/67375/WNG-Z4VQ4N1T-S</idno>
		<idno type="istexId">C6E4705947742BE17520A072FB9DDC07D869E80C</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">J Gastroenterol Hepatol</title>
		<idno type="ISSN">0815-9319</idno>
		<idno type="ISSNe">1440-1746</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="794" to="800" />
			<date type="published" when="2007-06" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prevalence and Predictors of Hepatic Steatosis in Adults With Newly Diagnosed Chronic Liver Disease due to Hepatitis C</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amanda</forename><forename type="middle">V</forename><surname>Hayman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andre</forename><forename type="middle">N</forename><surname>Sofair</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Michele</forename><surname>Manos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ann</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Norah</forename><surname>Terrault</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Grace</forename><forename type="middle">Van</forename><surname>Ness</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicole</forename><surname>Stabach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><surname>Rumore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><surname>Corless</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Beth</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephanie</forename><surname>Bialek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Atif</forename><surname>Zaman</surname></persName>
		</author>
		<idno type="DOI">10.1097/md.0b013e3181b954f4</idno>
		<idno type="PMID">19745689</idno>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<title level="j" type="abbrev">Medicine</title>
		<idno type="ISSN">0025-7974</idno>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="302" to="306" />
			<date type="published" when="2009-09" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Adam</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Catriona</forename><forename type="middle">A</forename><surname>Mclean</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">S</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stuart</forename><forename type="middle">K</forename><surname>Roberts</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2005.01.031</idno>
		<idno type="PMID">15876468</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Hepatology</title>
		<title level="j" type="abbrev">Journal of Hepatology</title>
		<idno type="ISSN">0168-8278</idno>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="38" to="44" />
			<date type="published" when="2005-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Steatosis as a co-factor in chronic liver diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marcello</forename><surname>Persico</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Iolascon</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v16.i10.1171</idno>
		<idno type="PMID">20222159</idno>
		<idno type="PMCID">PMC2839168</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Gastroenterology</title>
		<title level="j" type="abbrev">WJG</title>
		<idno type="ISSN">1007-9327</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">1171</biblScope>
			<date type="published" when="2010" />
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xi</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi-Peng</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi-Da</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">You-Ming</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lin</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chuan-Qing</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0034198</idno>
		<idno type="PMID">22479562</idno>
		<idno type="PMCID">PMC3316632</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0034198&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e34198</biblScope>
			<date type="published" when="2012-03-30" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bahadir</forename><surname>Ceylan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ferhat</forename><surname>Arslan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ayse</forename><surname>Batirel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Muzaffer</forename><surname>Fincanci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cem</forename><surname>Yardimci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Esra</forename><surname>Fersan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Esra</forename><surname>Pasaoglu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mesut</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ali</forename><surname>Mert</surname></persName>
		</author>
		<idno type="DOI">10.5152/tjg.2015.150348</idno>
		<idno type="PMID">26674977</idno>
		<ptr type="open-access" target="https://www.turkjgastroenterol.org/Content/files/Kapak%20ve%20on%20sayfalar(5).pdf" />
	</analytic>
	<monogr>
		<title level="j">The Turkish Journal of Gastroenterology</title>
		<title level="j" type="abbrev">Turk J Gastroenterol</title>
		<idno type="ISSN">1300-4948</idno>
		<idno type="ISSNe">2148-5607</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="42" to="46" />
			<date type="published" when="2016-01-04" />
			<publisher>AVES Publishing Co.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Chinese Society of Hepatology</title>
		<imprint/>
	</monogr>
	<note>Chinese Medical Association</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Chinese Society of Infectious Diseases</title>
	</analytic>
	<monogr>
		<title level="j">Chinese Medical Association</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinlin</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guiqiang</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fusheng</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lanjuan</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qinghua</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingmin</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhongping</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jidong</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jifang</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fengmin</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qing</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lai</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.14218/jcth.2016.00019</idno>
		<idno type="PMID">29226097</idno>
		<idno type="PMCID">PMC5719188</idno>
		<ptr type="open-access" target="http://publine.xiahepublishing.com/journals/10.14218/JCTH.2016.00019.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical and Translational Hepatology</title>
		<idno type="ISSN">2225-0719</idno>
		<idno type="ISSNe">2310-8819</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="297" to="318" />
			<date type="published" when="2017-11-12" />
			<publisher>Xia &amp; He Publishing</publisher>
		</imprint>
	</monogr>
	<note>The guideline of prevention and treatment for chronic hepatitis B: a 2015 update</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Gan Zang Bing Za Zhi</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="888" to="905" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Quantitative grading using grey relational analysis on ultrasonographic images of a fatty liver</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Icer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Coskun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ikizceli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Syst</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2521" to="2528" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Ates</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yalniz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v17.i40.4517</idno>
		<idno type="PMID">22110283</idno>
		<idno type="PMCID">PMC3218143</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Gastroenterology</title>
		<title level="j" type="abbrev">WJG</title>
		<idno type="ISSN">1007-9327</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">40</biblScope>
			<biblScope unit="page">4517</biblScope>
			<date type="published" when="2011" />
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
